Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 11/20 | 0.53 |
| ▸ | FPR3 | P25089 | 1/20 | 0.53 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.53 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4634971 | 0.92 | CCR1 (0.57) | CCR1FPR3GPR65GPR35LMNA | |
| SCHEMBL4634359 | 0.91 | CCR1 (0.54) | CCR1FPR3GPR65GPR35LMNA | |
| SCHEMBL5671905 | 0.91 | CCR1 (0.52) | CCR1FPR3GPR65GPR35LMNA | |
| SCHEMBL4634270 | 0.90 | CCR1 (0.57) | CCR1FPR3GPR65GPR35LMNA | |
| SCHEMBL4634980 | 0.89 | CCR1 (0.59) | CCR1FPR3GPR65GPR35LMNA | |
| SCHEMBL4635131 | 0.89 | CCR1 (0.58) | CCR1FPR3GPR65GPR35LMNA | |
| SCHEMBL4634727 | 0.88 | CCR1 (0.57) | CCR1FPR3GPR65GPR35LMNA | |
| SCHEMBL4635140 | 0.88 | CCR1 (0.57) | CCR1FPR3GPR65GPR35LMNA | |
| SCHEMBL4635055 | 0.87 | CCR1 (0.55) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL4634876 | 0.87 | CCR1 (0.53) | CCR1FPR3GPR65GPR35LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167044-A1 | Piperidine derivatives and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167044-A1 | Piperidine derivatives and their use as anti-inflammatory agents | CCR1, CCR2, CCR3 | CCR1 1/4885FPR3 90/4885GPR65 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.